What Would It Take For Pfizer To Cut Its Dividend?

Pfizer (PFE) has returned 23.1% over the past year and trades about 5% below its three-year high. Yet one question keeps coming back on its earnings calls: would it ever cut the dividend? An analyst asked it outright on the August call, and another tied it to a big acquisition in May. So what would a cut take, and what would it change?

Why Do Analysts Keep Asking About Pfizer’s Dividend?

Because the patent clock is running. Management expects patent expiries to weigh on results mainly from 2026 through 2028. In May the CEO put the revenue at stake at $14 billion to $15 billion, down from an earlier estimate of $17 billion. Set against the $63.7 billion of revenue Pfizer booked over the last twelve months, that revenue at stake is more than a fifth of a year’s sales.

On the August call the CEO answered that the dividend holds even in the most stretched scenarios Pfizer runs, and will grow again after the patent-expiry period. Management also expects leverage, 2.7 times at the end of the second quarter of 2026, to stay near that level or rise modestly through the transition.

What Would Ending The Dividend Free Up For Pfizer?

In the first half of 2026 Pfizer paid $4.9 billion in dividends. Scrapping the dividend outright would have freed all of that cash. Reported operating cash flow was $3.45 billion in the first half of 2026, but that absorbed Pfizer’s final $2.6 billion TCJA repatriation tax payment. Adjusted for that one-time outflow, operating cash generation reached approximately $6.05 billion, covering the $4.9 billion dividend payout with room to spare.

An analyst in May linked a possible cut to a transformative acquisition. The CEO replied that a big merger is not high on the list for now, because the next few years are for Pfizer’s AI transformation, which a mega merger would disrupt. On the August call Pfizer put its deal capacity at about $6 billion, which the analyst who asked about a cut called somewhat constraining.

Operating income also covered interest about 6 times over the last twelve months. On these numbers, a cut would more likely follow a choice than a cash squeeze.

How Would You Know Pfizer’s Payout Was Under Strain?

Start with what already supports the payout. Management expects about $9.7 billion of total net savings from its cost programs through 2029, and expects the Vyndamax patent settlement to lift cash flow after 2028. Launched and acquired products, including Padcev and NURTEC, brought in $3.2 billion in the second quarter of 2026, up 18% excluding currency moves.

The first signpost is whether leverage climbs more than modestly from 2.7 times in the next report, expected around November 2, 2026. The second is any deal that outgrows Pfizer’s deal capacity, since that is the choice a cut could follow.

Owning Pfizer has also meant sitting through a fall of about 31% at its worst over the past three years. Our drawdown defenders ranking shows which stocks have held up best when markets turn.

So Should You Own Pfizer For The Dividend Alone?

Perhaps, but only if you would hold the shares through a cut without selling. Adjusted operating cash flow covered the dividend in the first half of 2026, but the patent-expiry period runs through 2028. Before you decide, compare how other stocks held up through their own bad stretches. If you would rather not rest your income on one promise, look at the Trefis High Quality Portfolio instead. That portfolio has a track record of outpacing the three major indices.